Population-Based Analysis of the Risk of Mycobacterial Infections Associated With Immune Checkpoint Inhibitors

Abstract In this population-based study, we examined the risk of nontuberculous mycobacterial disease associated with immune checkpoint inhibitors among people with cancer. Using a nested case-control design, we identified 184 cases and 714 matched controls; there was no significant association on conditional logistic regression (adjusted odds ratio, 0.51 [95% confidence interval, .17–1.50]; P = .22).